Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05914987 · ClinicalTrials.gov registry record
Determining Individualized Cancer Therapy in Pancreatic Cancer
A clinical trial of Pancreatic Neoplasms, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05914987: Recruiting study of Pancreatic Neoplasms, sponsored by Medical College of Wisconsin.
NCT05914987 is a study of Pancreatic Neoplasms that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 1,000 participants, above the 568-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05914987, a study of Pancreatic Neoplasms, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.
Primary Outcome
This measure is the number of study subject's whose treating physician prescribes and subsequently receives the therapeutic recommendation of the Molecular Tumor Board.
Conditions Studied
Interventions
- OTHER Targeted Therapy
Study Locations (1)
Wisconsin
- Froedtert Hospital and the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2033-08-01 |
What NCT05914987 shows while recruiting
NCT05914987 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 568-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (76% higher).
The record links to 1 condition, with Pancreatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Targeted Therapy is the first listed.
NCT05914987 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05914987 about?
NCT05914987 is a clinical study titled "Determining Individualized Cancer Therapy in Pancreatic Cancer". This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patie...
What is the current status of trial NCT05914987?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2023-12-04. Estimated completion is 2033-08-01.
What conditions does trial NCT05914987 study?
This clinical trial studies the following conditions: Pancreatic Neoplasms.
What interventions are being tested in trial NCT05914987?
The interventions under investigation include: Targeted Therapy (OTHER).
Who is sponsoring clinical trial NCT05914987?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05914987 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05914987's enrollment target sits among peer trials
1,000 4th of 30 higher than 25 of 30 other Pancreatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
RECRUITING
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RECRUITING
-
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
RECRUITING
-
UCSF PANC Cyst Registry
RECRUITING
-
Pancreatic Cancer Detection Consortium
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI